Literature DB >> 35915323

Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Andreas A Giannopoulos1, Ronny R Buechel1, Philipp A Kaufmann2.   

Abstract

Pathologic hypertrophy of the cardiac muscle is a commonly encountered phenotype in clinical practice, associated with a variety of structural and non-structural diseases. Coronary microvascular disease is considered to play an important role in the natural history of this pathological phenotype. Non-invasive imaging modalities, most prominently positron emission tomography and cardiac magnetic resonance, have provided insights into the pathophysiological mechanisms of the interplay between hypertrophy and the coronary microvasculature. This article summarizes the current knowledge on coronary microvascular dysfunction in the most frequently encountered forms of pathologic hypertrophy.
© 2022. The Author(s).

Entities:  

Keywords:  CMD; CMR; Coronary microvascular disease; cardiac PET; coronary flow reserve; left ventricular hypertrophy

Year:  2022        PMID: 35915323     DOI: 10.1007/s12350-022-03040-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  84 in total

Review 1.  Hypertrophic Cardiomyopathy: Clinical Update.

Authors:  Jeffrey B Geske; Steve R Ommen; Bernard J Gersh
Journal:  JACC Heart Fail       Date:  2018-04-11       Impact factor: 12.035

2.  Myocardial Histopathology in Patients With Obstructive Hypertrophic Cardiomyopathy.

Authors:  Hao Cui; Hartzell V Schaff; Juliano Lentz Carvalho; Rick A Nishimura; Jeffrey B Geske; Joseph A Dearani; Brian D Lahr; Alexander T Lee; J Martijn Bos; Michael J Ackerman; Steve R Ommen; Joseph J Maleszewski
Journal:  J Am Coll Cardiol       Date:  2021-05-04       Impact factor: 24.094

3.  Coronary microvascular dysfunction in hypertrophy and heart failure.

Authors:  Paolo G Camici; Carsten Tschöpe; Marcelo F Di Carli; Ornella Rimoldi; Sophie Van Linthout
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

4.  Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.

Authors:  Stefan A J Timmer; Tjeerd Germans; Wessel P Brouwer; Mark Lubberink; Jolanda van der Velden; Arthur A M Wilde; Imke Christiaans; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Heart Fail       Date:  2011-10-21       Impact factor: 15.534

Review 5.  Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography.

Authors:  Stefan A J Timmer; Paul Knaapen
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-11-14       Impact factor: 6.875

6.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

Review 7.  Hypertrophy of the heart: a new therapeutic target?

Authors:  Norbert Frey; Hugo A Katus; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2004-04-06       Impact factor: 29.690

Review 8.  Coronary microvascular dysfunction.

Authors:  Paolo G Camici; Filippo Crea
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

Review 9.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Steve R Ommen; Seema Mital; Michael A Burke; Sharlene M Day; Anita Deswal; Perry Elliott; Lauren L Evanovich; Judy Hung; José A Joglar; Paul Kantor; Carey Kimmelstiel; Michelle Kittleson; Mark S Link; Martin S Maron; Matthew W Martinez; Christina Y Miyake; Hartzell V Schaff; Christopher Semsarian; Paul Sorajja
Journal:  Circulation       Date:  2020-11-20       Impact factor: 29.690

10.  Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy.

Authors:  Paul Knaapen; Tjeerd Germans; Paolo G Camici; Ornella E Rimoldi; Folkert J ten Cate; Jurrien M ten Berg; Pieter A Dijkmans; Ronald Boellaard; Willem G van Dockum; Marco J W Götte; Jos W R Twisk; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-12-21       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.